Purpose

The goal of this clinical trial is to reduce heavy drinking and enhance medication for opioid use disorder (MOUD) outcomes in individuals receiving MOUD. The main questions it aims to answer are: - Does the brief, digitally-enhanced, virtual psychotherapeutic intervention, called Managing Physical Reactions to Overwhelming Emotions (IMPROVE), impact daily alcohol use and MOUD adherence? - Does the intervention change self-report and physiological responses to intolerance to uncertainty and anxiety sensitivity? Researchers will compare IMPROVE to a control intervention (health education treatment) to see if IMPROVE impacts daily alcohol use and MOUD adherence. Participants will: - Complete a baseline electroencephalography (EEG) and self-report questionnaires. - Complete three one-hour intervention sessions (IMPROVE or control) each one week a part. - Complete a post-intervention EEG and self-report questionnaires. - Complete five ecological momentary assessment (EMA) surveys a day for 21 days. - Complete self-report questionnaires one-month after their last intervention session.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Enrolled in outpatient medication for opioid use disorder (MOUD) program (within the past month) - Heavy alcohol user defined using the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria (i.e., consume 8+/15+ drinks per week [women/men] with at least two binge episodes [4/5+ drinks for women/men in a 2 hour period] in the past month) - Elevated psychological distress defined as a total score of > 12 on the Kessler Psychological Distress Scale (K10; 0 to 40 range) - 18 years of age or older - Can read and comprehend English

Exclusion Criteria

  • Do not pass the informed decision-making capacity screener, suggesting cognitive impairment or an inability to provide informed consent - Presence of a psychiatric or medical condition that would prevent them from providing informed consent or participating in the treatments (e.g., psychosis, mania, acute intoxication) - Current comorbid moderate to severe substance use disorder other than alcohol and opioids - Limited or no access to a smart phone that is compatible with the mobile application - Participation in Phase One - Possibility of being pregnant (by self-report) - Current suicidal or homicidal intent indicating a need for immediate hospitalization or treatment as determined by clinical interviewer

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Participants will be randomized to receive one of two possible interventions.
Primary Purpose
Treatment
Masking
Single (Participant)
Masking Description
Participants will be blind to the condition.

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Managing Physical Reactions to Overwhelming Emotions (IMPROVE)
In this arm, participants will receive the IMPROVE intervention, a clinician-delivered protocol targeting anxiety and uncertainty.
  • Behavioral: Managing Physical Reactions to Overwhelming Emotions (IMPROVE)
    Participants may be randomized to IMPROVE. IMPROVE is a three session virtual intervention delivered by research clinicians and augmented by a mobile application. The treatment is designed to target and reduce distress contributing to heavy alcohol use during medication for opioid use disorder treatment.
Active Comparator
Health Education Training (HET)
In this arm, participants will receive a clinician-delivered protocol with a digital component, called HET. HET focuses on healthy living more broadly and does not include information about anxiety or uncertainty.
  • Behavioral: Health Education Training (HET)
    Participants may be randomized to HET. HET is an active control intervention that is equally intensive as IMPROVE It includes three virtual sessions and a mobile application. HET is designed to target healthy lifestyle behaviors such as diet and sleep.

Recruiting Locations

Ohio State University
Columbus 4509177, Ohio 5165418 43210
Contact:
Stephanie Gorka, PhD
614-366-1027
stephanie.gorka@osumc.edu

More Details

NCT ID
NCT06718491
Status
Recruiting
Sponsor
Ohio State University

Study Contact

Stephanie Gorka, PhD
614-366-1027
stephanie.gorka@osumc.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.